1Q Revenues: $457.4 million (+13%)
1Q Earnings: $28.3 million (loss of $22.1 million 1Q16)
Comments: The DPS segment grew 6% to $275.2 million due to higher product volumes, partially offset by delays in customer-supplied materials. The PDS segment was up 8% to $52.3 million, driven by demand for sterile and low-solubility services. The DSS segment grew 31% to $129.9 million, with growth in demand for both biologics and API.